AST to Platelet Ratio Index (APRI)

ورودی‌های بالینی بیمار

حداقل ۱ — حداکثر ۲۰۰۰ • واحد: U/L

حداقل ۱۰ — حداکثر ۱۰۰ • واحد: U/L

حداقل ۱۰ — حداکثر ۱۰۰۰ • واحد: × 10³/µL

پنل نتیجه و تصمیم بالینی
در انتظار ورودی‌ها
apri score
—index
آماده برای ارزیابی

پارامترهای بالینی بیمار را در فرم روبرو وارد کنید و روی «محاسبه» کلیک نمایید تا نمره، طبقه خطر و اقدامات فوری نمایش داده شوند.

طبقات خطر و بازه‌های امتیاز:
  • Low Risk0–0.3
  • Low-Intermediate Risk0.3–0.5
  • Intermediate Risk0.5–1.5
  • High Risk1.5–2
Direct Clinical Answer

The AST to Platelet Ratio Index (APRI) calculates evaluating end-stage liver disease severity, short-term mortality, and liver transplant waitlist prioritization. Key inputs include ast. Scores guide managing portal hypertension complications, referring for liver transplant evaluation, and supportive care. This standardized assessment improves clinical decision safety and bedside patient management.

Clinical Guidelines & Evidence

Determines the likelihood of hepatic fibrosis and cirrhosis in patients with hepatitis C using readily available laboratory values.

Clinical Indication

The AST to Platelet Ratio Index (APRI) is indicated for bedside clinical practice to support Determines the likelihood of hepatic fibrosis and cirrhosis in patients with hepatitis C using readily available laboratory values.. It assists healthcare providers in standardizing clinical assessment and therapeutic decision-making.

Target Population

Target population comprises Patients with decompensated liver cirrhosis, acute liver failure, portal hypertension, ascites, or end-stage liver disease awaiting organ allocation. Clinical application is indicated across Hepatology clinics, liver transplant assessment centers, gastroenterology wards, and liver ICUs.

Limitations & Contraindications

Due to muscle wasting and reduced hepatic creatine synthesis, serum creatinine routinely underestimates renal dysfunction in cirrhosis.

Clinical Pearls & Action Plan

Preventing spontaneous bacterial peritonitis (SBP), managing variceal hemorrhage, and monitoring hepatic encephalopathy are top clinical priorities.

Formula & Variables:

APRI = [(AST/AST upper limit of normal) × 100] / Platelet count (×10³/µL)

Input Parameters

NameTypeRequiredDescription
astfloatYesSerum aspartate aminotransferase (AST) level(U/L)
ast_upper_limitfloatYesUpper limit of normal for AST (typically 40 U/L for males, 32 U/L for females, or laboratory-specific reference range)(U/L)
platelet_countfloatYesPlatelet count(× 10³/µL)

Score Interpretation & Guidance

RangeStageDescription
0–0.3Low RiskRules out significant fibrosis
0.3–0.5Low-Intermediate RiskLow probability of cirrhosis
0.5–1.5Intermediate RiskIndeterminate risk
1.5–2High RiskSuggests significant fibrosis
2–100Very High RiskSuggests cirrhosis

Evidence-Based References (EBM)

  • Wai CT, Greenson JK, Fontana RJ, et al. A simple noninvasive index can predict both significant fibrosis and cirrhosis in patients with chronic hepatitis C. Hepatology. 2003;38(2):518-26.
  • Shaheen AA, Myers RP. Diagnostic accuracy of the aspartate aminotransferase-to-platelet ratio index for the prediction of hepatitis C-related fibrosis: a systematic review. Hepatology. 2007;46(3):912-21.
  • Lin ZH, Xin YN, Dong QJ, et al. Performance of the aspartate aminotransferase-to-platelet ratio index for the staging of hepatitis C-related fibrosis: an updated meta-analysis. Hepatology. 2011;53(3):726-36.

Related calculators